1. Home
  2. TENX vs AIRS Comparison

TENX vs AIRS Comparison

Compare TENX & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.64

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$4.70

Market Cap

328.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
AIRS
Founded
1967
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
328.7M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
TENX
AIRS
Price
$13.64
$4.70
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
898.1K
669.7K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$151,818,000.00
Revenue This Year
N/A
$5.19
Revenue Next Year
N/A
$5.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.67
$1.51
52 Week High
$18.38
$12.00

Technical Indicators

Market Signals
Indicator
TENX
AIRS
Relative Strength Index (RSI) 67.28 46.21
Support Level $13.16 $2.40
Resistance Level $14.15 $5.79
Average True Range (ATR) 0.72 0.44
MACD 0.30 -0.14
Stochastic Oscillator 99.40 13.26

Price Performance

Historical Comparison
TENX
AIRS

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.

Share on Social Networks: